These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12619369)

  • 21. [Hypertension: improved therapy adherence after switch to a fixed drug combinations].
    MMW Fortschr Med; 2012 Mar; 154(5):78-9. PubMed ID: 22624273
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
    Conen D; Everett BM; Glynn RJ; Ridker PM
    Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database.
    Jackson KC; Sheng X; Nelson RE; Keskinaslan A; Brixner DI
    Clin Ther; 2008 Aug; 30(8):1558-63. PubMed ID: 18803997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Successful high dosage fixed combination. 7 of 10 patients achieve target blood pressure].
    MMW Fortschr Med; 2006 Nov; 148(45):59. PubMed ID: 17615754
    [No Abstract]   [Full Text] [Related]  

  • 26. [Hypertension and diabetic nephropathy, a dangerous duo].
    Hausberg M; Hohage H; Kosch M
    Med Klin (Munich); 2005 Nov; 100(11):729-37; quiz 738-9. PubMed ID: 16328181
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hypertension therapy. Does AT-1 blocker help love life?].
    MMW Fortschr Med; 2003 Feb; 145(9):57. PubMed ID: 12666537
    [No Abstract]   [Full Text] [Related]  

  • 29. Interesting findings in the VALERIA trial.
    Rosa EM; Viecceli C
    J Hypertens; 2009 Apr; 27(4):902; author reply 902-3. PubMed ID: 19300116
    [No Abstract]   [Full Text] [Related]  

  • 30. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).
    Tardif JC; Curnew GP; Leclerc JM; Rehel B
    Can J Clin Pharmacol; 2008; 15(2):e177-87. PubMed ID: 18515919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Blood pressure lowering and risk reduction under treatment with valsartan and its combination with hydrochlorothiazide (HCT)].
    Scholze J; Müller U
    MMW Fortschr Med; 2006 Oct; 148(42):48. PubMed ID: 17621800
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiotensin receptor blockers: dose does matter.
    Sarzani R; Dessì-Fulgheri P; Rappelli A
    J Hypertens; 2008 Mar; 26(3):607-8; author reply 608. PubMed ID: 18300874
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
    Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
    Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
    Kondrack R; Mohiuddin S
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nebivolol and valsartan: useful treatment for hypertension?
    Waeber B; Feihl F
    Lancet; 2014 May; 383(9932):1864-6. PubMed ID: 24881977
    [No Abstract]   [Full Text] [Related]  

  • 39. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
    Serebruany VL; Pokov AN; Malinin AI; O'Connor C; Bhatt DL; Tanguay JF; Sane DC; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):92-9. PubMed ID: 16368298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.